Fig. 5

Predicting immunotherapy in patients with colon cancer. (A) An analysis of differences in CDH3 expression and immune cells in colon cancer. Each dot in the figure represents an immune cell subtype, and the color and position of the dot reflect its association with CDH3 expression and its P value. (B) CDH3 expression in the TCGA database versus immune infiltration score, immune score, and stromal score immune infiltration versus clinical outcome in the TCGA-COAD dataset. (C, D) Clinical stage (M0, M1) with immune infiltration assessment. (E) TIDE scores and T cell dysfunction scores for colon cancer patients with low CDH3 expression and those with high CDH3 expression. TIDE score can be used to predict the response to immune checkpoint blockade (ICB) therapy. Low TIDE score indicates that the possibility of tumor immune escape is low and patients are more likely to benefit from anti-PD-1 /CTLA4 treatment. The figure shows that the TIDE score and dysfunction score were lower in the high CDH3 expression group, suggesting that patients in this group may be better candidates for ICB treatment. (F) The results of the correlation analysis between CDH3 gene expression and immune checkpoint related gene expression. Each point in the figure represents an immune checkpoint-related gene, and the direction and slope of the line reflect its association with CDH3 expression. (G) The association between CDH3 expression and immune response by the TIDE algorithm. Groups of CDH3 expression levels are represented on the patients’ response to immunotherapy (as non-response or response) is represented on the ordinate. This graph is used to show the relationship between CDH3 expression and immunotherapy response to aid in determining the role of CDH3 in immunotherapy